Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the
combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma
(PDAC)